X

Indication

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia... read more

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis. read more

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.

Limitations of Use

  • Aranesp® has not been shown to improve quality of life, fatigue, or patient well-being.
  • Aranesp® is not indicated for use as a substitute for red blood cell transfusions in patients who require immediate correction of anemia.
› Email› Print

Transfusions have potential benefits and risks1-3

  • According to the National Kidney Foundation KDOQI, despite use of pharmacologic agents for the treatment of anemia, blood transfusions are occasionally required, particularly in the setting of acute bleeding.4
  • RBC transfusions should be used judiciously in patients with CKD, especially because of the potential development of sensitivity affecting future kidney transplant.4

Potential Benefits1

Potential Risks1-3

  • Prompt increase in RBCs
  • Improved oxygen delivery to tissues
  • Avoidance of myocardial ischemia
  • Relief of acute symptoms
  • Allergic reactions
  • Febrile reactions
  • Hemolytic reactions
  • Immune-mediated reactions, including:

    - Increased panel-reactive antibodies (PRA)

    - Transfusion-related acute lung injury (TRALI)

  • Nonimmunologic reactions (eg, fluid overload, hyperkalemia, iron overload, transfusion-associated circulatory overload [TACO], circulatory/cardiovascular adverse events)
  • Infections

Reducing the risk of alloimmunizations and/or other RBC transfusion-related risks is a goal for patients with CKD.5

Limitations of Use

  • Aranesp® has not been shown to improve quality of life, fatigue, or patient well-being.
  • Aranesp® is not indicated for use as a substitute for red blood cell transfusions in patients who require immediate correction of anemia.

Scroll down for additional
Important Safety Information.

Abbreviations and References:
CKD = chronic kidney disease; KDOQI = National Kidney Foundation Kidney Disease Outcomes Quality Initiative; RBC = red blood cell.
References: 1. Dzieczkowski JS, Anderson KC. Transfusion biology and therapy. In: Fauci AS, Kasper DL, Longo DL, et al, eds. Harrison’s Principles of Internal Medicine. 17th ed. New York, NY: McGraw-Hill; 2008:707-713. 2. Skeate RC, Eastlund T. Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload. Curr Opin Hematol. 2007;14:682-687. 3. United States Renal Data System. 2004 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2004. 4. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47:S1-S146. 5. Aranesp® (darbepoetin alfa) prescribing information, Amgen.